Sugi Predict

Sugi Predict / Compounds / SCHEMBL421369

SCHEMBL421369

SCHEMBL421369

Brc1cnc2[nH]ccc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 16/20 1.00
▸ RIPK1 Q13546 1/20 0.50
▸ ABL1 P00519 1/20 0.42
▸ RET P07949 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ CDK7 P50613 1/20 0.42
▸ CDK5 Q00535 1/20 0.42
▸ PRKAA1 Q13131 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ JAK3 P52333 2/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ PRKCI P41743 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29414803 1.00 MAPK1 (1.00) MAPK1RIPK1ABL1RETKDR
SCHEMBL20674184 0.79 MAPK1 (0.66) MAPK1RIPK1JAK3JAK2JAK1
SCHEMBL10113284 0.75 MAPK1 (0.60) MAPK1RIPK1JAK3JAK2JAK1
SCHEMBL9989891 0.75 MAPK1 (0.60) MAPK1RIPK1JAK3JAK2JAK1
SCHEMBL30259218 0.75 MAPK1 (0.60) MAPK1RIPK1JAK3JAK2JAK1
SCHEMBL12657772 0.75 MAPK1 (0.60) MAPK1RIPK1JAK3JAK2JAK1
SCHEMBL650714 0.75 MAPK1 (0.60) MAPK1RIPK1JAK3JAK2JAK1
SCHEMBL21821052 0.75 MAPK1 (0.60) MAPK1RIPK1JAK3JAK2JAK1
SCHEMBL2619257 0.75 MAPK1 (0.60) MAPK1RIPK1JAK3JAK2JAK1
SCHEMBL30259044 0.75 MAPK1 (0.60) MAPK1RIPK1JAK3JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102627646-A Preparation method of 3-iodo-5-bromo-4, 7-diazaindole STONE LAKE PHARMA TECH CO LTD 2012-08-08 — — CN claimed
EP-4698531-A1 PYRROLOPYRAZINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF Sanofi (FR) 2026-02-25 — — EP disclosed
EP-4688768-A1 NOVEL METTL3 INHIBITORS AND USE THEREOF IN THERAPY Novalix (FR) 2026-02-11 — — EP disclosed
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS ACLARIS THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
US-20260028347-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2026-01-29 — — US disclosed
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 — — US disclosed
US-20260008760-A1 DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF INSMED INCORPORATED 2026-01-08 — — US disclosed
EP-4655301-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING Epirium Bio Inc. (US) 2025-12-03 — — EP disclosed
EP-4655300-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING Epirium Bio Inc. (US) 2025-12-03 — — EP disclosed
WO-2025245484-A1 FOXN1 ACTIVATORS THYMOFOX INC. (US) 2025-11-27 — — WO disclosed
US-7452993-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2008-11-18 — — US disclosed
US-7452993-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2008-11-18 — — US disclosed
WO-2008124850-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed
WO-2008124850-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 — — US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 — — US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 — — US disclosed
EP-1778687-A2 FUSED RING HETEROCYCLE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2007-05-02 — — EP disclosed
US-20060035898-A1 Fused ring heterocycle kinase modulators STRUCTURAL GENOMIX, INC. (US) 2006-02-16 — — US disclosed
WO-2006015124-A2 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2006-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS JAK3, JAK1, JAK2 MAPK1 139/4885RIPK1 517/4885ABL1 530/4885
US-20060035898-A1 Fused ring heterocycle kinase modulators MAP3K20, TTK, MAP3K19 MAPK1 319/4885RIPK1 250/4885ABL1 141/4885
US-20260028347-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPK1 3157/4885RIPK1 3596/4885ABL1 3625/4885
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, TTK, MAP3K19 MAPK1 319/4885RIPK1 250/4885ABL1 141/4885
US-20260008760-A1 DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF DPP9, DPP7, DPP4 MAPK1 903/4885RIPK1 4220/4885ABL1 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.